International Journal of Cardiology
Volume 135, Issue 2 , Pages 156-161 , 26 June 2009

Elevated serum alkaline phosphatase and peripheral arterial disease in the United States National Health and Nutrition Examination Survey 1999–2004

  • Bernard M.Y. Cheung

      Affiliations

    • Department of Medicine, University of Hong Kong, Hong Kong SAR, China
    • Research Centre of Heart, Brain, Hormone and Healthy Ageing, University of Hong Kong, Hong Kong SAR, China
    • Corresponding Author InformationCorresponding author. Department of Clinical Pharmacology, University of Birmingham, Birmingham, B15 2TT, UK. Tel.: +44 121 4146874; fax: +44 121 4141355.
    • ,
  • Kwok Leung Ong

      Affiliations

    • Department of Medicine, University of Hong Kong, Hong Kong SAR, China
    • ,
  • Louisa Y.F. Wong

      Affiliations

    • Department of Medicine, University of Hong Kong, Hong Kong SAR, China

Received 30 November 2007 ,Revised 24 January 2008 ,Accepted 6 March 2008.

References 

  1. Sumner AD, Eid S, Parks A, Edris B, Reed III JF. Increasing prevalence of peripheral artery disease in the United States: results from the National Health and Nutrition Examination Survey (1999–2004). Circulation 2007; 116:II–780 (Abstract).
  2. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621
  3. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–743
  4. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999–2002. Am J Cardiol. 2005;96:1579–1583
  5. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96:655–658
  6. Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, 1999–2002. J Vasc Surg. 2006;44:319–324
  7. Menke A, Muntner P, Wildman RP, Dreisbach AW, Raggi P. Relation of borderline peripheral arterial disease to cardiovascular disease risk. Am J Cardiol. 2006;98:1226–1230
  8. Nasir K, Guallar E, Navas-Acien A, Criqui MH, Lima JA. Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999–2002. Arterioscler Thromb Vasc Biol. 2005;25:1966–1971
  9. Shankar A, Klein BE, Nieto FJ, Klein R. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis. 2008;196:749–755
  10. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004;109:3196–3201
  11. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–3147
  12. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240
  13. Fahrleitner-Pammer A, Obernosterer A, Pilger E, et al. Hypovitaminosis D, impaired bone turnover and low bone mass are common in patients with peripheral arterial disease. Osteoporos Int. 2005;16:319–324
  14. Fahrleitner A, Dobnig H, Obernosterer A, et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med. 2002;17:663–669
  15. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25:193–197
  16. National Health and Nutrition Examination Survey questionnaire, examination protocol and laboratory protocol. Hyattsville, Maryland: United States Department of Health and Human Services, Centers for Disease Control and Prevention, 1999–2000, 2001–2002 and 2003–2004. Available at: http://www.cdc.gov/nchs/data/nhanes. Accessed August 29, 2007.
  17. Newman AB, Siscovick DS, Manolio TA, et al. Ankle–arm index as a marker of atherosclerosis in the Cardiovascular Health Study: Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88:837–845
  18. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–2483
  19. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:69–75
  20. Corathers SD. Focus on diagnosis: the alkaline phosphatase level: nuances of a familiar test. Pediatr Rev. 2006;27:382–384
  21. Pennisi P, Signorelli SS, Riccobene S, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int. 2004;15:389–395
  22. Mangiafico RA, Russo E, Riccobene S, et al. Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women. J Bone Miner Metab. 2006;24:125–131
  23. Kaplow LS. Leukocyte alkaline phosphatase cytochemistry: applications and methods. Ann NY Acad Sci. 1968;155:911–947
  24. Maldonado O, Demasi R, Maldonado Y, Taylor M, Troncale F, Vender R. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol. 1998;27:342–345
  25. Cheung BM, Ong KL, Cheung RV, et al. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med. 2008;46:523–527
  26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  27. Tang FT, Chen SR, Wu XQ, et al. Hypercholesterolemia accelerates vascular calcification induced by excessive vitamin D via oxidative stress. Calcif Tissue Int. 2006;79:326–339
  28. Kim BJ, Yu YM, Kim EN, Chung YE, Koh JM, Kim GS. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women. Clin Endocrinol (Oxf). 2007;67:152–158
  29. Ali AT, Paiker JE, Crowther NJ. The relationship between anthropometry and serum concentrations of alkaline phosphatase isoenzymes, liver-enzymes, albumin, and bilirubin. Am J Clin Pathol. 2006;126:437–442
  30. Ali AT, Penny CB, Paiker JE, et al. Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1. Clin Chim Acta. 2005;354:101–109
  31. Ali AT, Penny CB, Paiker JE, Psaras G, Ikram F, Crowther NJ. The effect of alkaline phosphatase inhibitors on intracellular lipid accumulation in preadipocytes isolated from human mammary tissue. Ann Clin Biochem. 2006;43:207–213
  32. Lopez-Bermejo A, Botas P, Funahashi T, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004;60:256–263
  33. Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care. 2003;26:2015–2020
  34. Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007;49:1455–1461
  35. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med. 1993;117:187–190
  36. Gullihorn L, Karpman R, Lippiello L. Differential effects of nicotine and smoke condensate on bone cell metabolic activity. J Orthop Trauma. 2005;19:17–22

PII: S0167-5273(08)00506-8

doi: 10.1016/j.ijcard.2008.03.039

International Journal of Cardiology
Volume 135, Issue 2 , Pages 156-161 , 26 June 2009

Article Tools